← Back to Search

C1 esterase inhibitor

RUCONEST for Chronic Fatigue Syndrome

Phase 4
Waitlist Available
Research Sponsored by IMMUNOe Research Centers
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 17
Awards & highlights

Study Summary

This study is evaluating whether a drug may help improve neurological symptoms for individuals who have been infected with the SARS virus.

Eligible Conditions
  • Chronic Fatigue Syndrome
  • Coronavirus
  • Post-Viral Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 17
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 17 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immunological Biomarkers (Com)
Immunological Biomarkers (GAD)
Immunological Biomarkers (Ig)
+17 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RUCONESTActive Control1 Intervention
IV Ruconest
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

IMMUNOe Research CentersLead Sponsor
3 Previous Clinical Trials
56 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby Apr 2025